glenmark phamaceutical - This Document is confidential and...

Info iconThis preview shows pages 1–5. Sign up to view the full content.

View Full Document Right Arrow Icon
This Document is confidential and Serves information purpose only. Company Profile Glenmark January 21, 2010 P a g e | 1 InfoComm/CP/27
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
ABOUT Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. Glenmark is the leader in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). The company has a significant presence in branded generics markets across emerging economies including India. It also has a fast growing and robust US generics business. Its stock is listed on India’s two large stock exchanges, the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). Glenmark employs nearly 6000 people across its global operations across 80 countries. Glenmark was recently awarded by SCRIP, the largest selling and most respected pharmaceutical magazine in the world as the “Best Pharma company in the World – SME” and “Best company across Emerging markets” for 2008. Forbes, another leading international publication recognized Glenmark as the “Best Under a Billion Dollar companies in Asia” for 2008. In the area of drug discovery, Glenmark is focused in the areas of inflammation, metabolic disorders and pain. Presently, Glenmark has eight molecules in clinical trials. Most of them are either best-in-class or first-in-class with each have potential to become global blockbusters. Two of its molecules will enter Phase III trials. With this development, Glenmark takes a step closer to becoming the first Indian company to launch a truly innovative drug globally. VISION To emerge as a leading integrated research – based global pharmaceutical company. HISTORY 1977 Glenmark incorporated in India under the companies act under the name Glenmark Pharmaceutical Limited. 1979 Enters dermatology market with the launch of "Candid Cream". January 21, 2010 P a g e | 2 InfoComm/CP/27
Background image of page 2
This Document is confidential and Serves information purpose only. 1980 Starts Export business. 1983 First manufacturing facility commissioned at Nasik. 1987 Ascoril Launched. 1989 Operations started in Afghanistan, Srilanka, Kenya and Mauritius. 1996 Incorporated Glenmark Exports Private Limited, a wholly owned subsidiary to consolidate its position in international business. 1999 Started marketing products in Brazil. 2000 Announces its IPO issue oversubscribed 65 times. Market capitalization at USD 40mn. Enters the Diabetes segment. Acquires three brands from Lyka Labs. January 21, 2010 P a g e | 3 InfoComm/CP/27
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
2001 Launches API manufacturing business. 2002 Acquires an API manufacturing facility at Ankleshwar, Gujarat from GlaxoSmithKline Pharmaceuticals Ltd. 2004
Background image of page 4
Image of page 5
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 03/21/2010 for the course KNOWLEDGE 5654 taught by Professor Mr.david during the Spring '10 term at IESE Business School.

Page1 / 14

glenmark phamaceutical - This Document is confidential and...

This preview shows document pages 1 - 5. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online